Beyond long COVID — how reinfections could be causing silent long-term organ damage
COVID may no longer be considered an official global emergency, but mounting scientific evidence suggests every COVID infection a person gets increases their risk of developing long-term health issues.
"There is no such thing as a COVID infection without consequence," says long COVID researcher, David Putrino, from the Icahn School of Medicine at Mount Sinai in New York.
The long-term effects can show up as long COVID, with symptoms such as shortness of breath, digestive problems, fast or irregular heartbeats, extreme fatigue and brain fog, or as silently accumulating cellular or organ damage.
Putrino has been studying the lingering effects of COVID since early in the pandemic five years ago. Here is part of his conversation with Quirks & Quarks host Bob McDonald.
What kind of cumulative, silent damage can a COVID infection cause, beyond long COVID?
There is more and more literature emerging to show that, beyond long COVID, there are also effects that SARS-CoV-2 infections are having on the bodies of the general public that manifest in a way that might be viewed as silent. So what I mean by that is no one's going to their doctor and saying "I feel different" or "I feel as though my functional status has changed," but what's happening is, silently in the background, things are changing.
For the longest time in the field of immunology, there was the sort of adage that your immune system needs to be tested every now and again to stay strong. That's an old-fashioned idea.
A good example of that is the effect that SARS-CoV-2 infections can have on cognition. There was a recent 2024 study that showed us that individuals who survive an acute COVID-19 infection — these are not individuals who are getting diagnosed with long COVID — on average will lose somewhere in the neighbourhood of two to six IQ points per infection.
Really, with each infection?
According to the most recent study, yes. So there is a cumulative effect that can be occurring with each infection.
Early in the pandemic, we actually published a paper where we showed that, even in animal models — when we infected mice with a very, very mild case of SARS-CoV-2 infection — which only caused lung inflammation, we still saw these inflammatory chemicals called chemokines emerging from the infected lungs and starting to attack central nervous system structures such as the spinal cord and the brain.
Wow. So in other words, COVID is doing more than just infecting the lungs; it's going to other parts of the body.
Exactly. You know, this is a virus that, once it enters the body, is very capable of entering the bloodstream, creating immune responses that travel all over the body.
COVID is largely known as a respiratory disease. Can you walk me through the range of other body systems that might be vulnerable to long-term damage?
Well, in all of the peer-reviewed literature that has emerged on long COVID, we've seen that it is a very diffuse clinical syndrome where every single organ system can be affected. And at last count, over 200 symptoms have been catalogued as potential symptoms of long COVID.
When we actually dig into the science of why long COVID is causing the symptoms that it's causing, we see that there are problems such as what we call " viral persistence." Meaning the SARS-CoV-2 virus is not being effectively cleared by the body and it's sticking around.
It's hiding out in different areas of the body in what we typically call "immune privileged sites," which mean that immune cells don't actually go there and can't sort of seek out and destroy the virus. So that can happen in a number of different locations in the body, which leads to a wide array of symptoms.
We also see that the virus can cause prolonged chronic inflammation that can be whole-body wide. So it can affect every single organ and so often, many of the symptoms that people are experiencing are more related to which organ is most susceptible to them given their past medical history.
So we see things that are quite insidious. People who were pre-diabetic are suddenly diabetic. People who were having a few issues with gallbladder, suddenly can't digest fat anymore.
Well, what is it about the coronavirus that enables it to spread throughout the body like that?
In 2021, two colleagues of mine published a really wonderful paper that I think is very prescient and it spoke about why SARS-CoV-2 presents such an increased threat to cause persistent symptoms. The reality of that situation is that this virus has a lot of very unique qualities that specifically cause immune damage to the host.
So it's not just about infecting you and causing respiratory illness and fever and all of the things that we usually get with the viral infection. This virus also specifically causes your immune system to become weaker.
It disrupts what we call "interferon signalling," which is part of the immune system that helps you to fight off infections or latent infections, such as Epstein Barr virus.
Typically our immune system can keep these things suppressed, but when SARS-CoV-2 enters the picture, it starts to cause altered interferon signalling. It causes immune damage and dysregulation.
Although your immune system can take on [a COVID] infection, you want to avoid testing it as much as possible because your body is sustaining damage with each infection that it survives.
And suddenly, not only does your body have trouble clearing the SARS-CoV-2 virus itself, but it also starts to have trouble keeping some of these other viruses that have been latent from reactivating and causing problems.
In addition to SARS-CoV-2's ability to dysregulate the immune system and suppress the immune system, the spike protein itself is very damaging to blood vessel structures as well as red blood cells and platelets themselves.
And so between those two features, the ability to dysregulate the immune system and the ability to cause systemic damage throughout the bloodstream, you have a very dangerous novel virus on your hands.
Well, if it has the ability to suppress the immune system, how does that affect our ability to fight off other external pathogens that we might be susceptible to?
It's something that we worry about a lot. In 2023, we published a paper in Nature where we showed that individuals with long COVID were much more likely than a cohort of healthy controls to express signs of what we call "T-cell exhaustion." Meaning that their T cells, which are parts of the immune system that are typically used to fight off infections, are starting to present as exhausted — that there has been a persistent stimulation of these T cells for long enough that their responses over time are starting to weaken.
As a result, in this study we saw immune dysregulation, we saw hormonal dysregulation, we saw reactivation of herpes viruses that were previously thought to be latent.
And as we have made leaps and bounds in our ability to understand the role of these persistent pathogens, these things that we used to think, "Everybody's got Epstein-Barr virus, but don't worry, it sort of just lays dormant in your body and it doesn't cause any trouble."
What we're learning is that, well, it very much can cause trouble. If it's mixed with another pathogen and that pathogen causes the reactivation, then people can get very, very sick.
For the longest time in the field of immunology, there was the sort of adage that your immune system needs to be tested every now and again to stay strong. That's an old-fashioned idea.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Japan Forward
4 hours ago
- Japan Forward
AI Tool 'KIBIT': A Game Changer in New Drug Development
このページを 日本語 で読む The COVID-19 pandemic reminded the world of the importance of drug discovery. However, modern drug discoveries require massive financial investment. Meanwhile, the use of artificial intelligence for AI drug discovery is gaining attention as a way to control soaring pharmaceutical prices. And a Japanese-made AI tool named 'KIBIT' is about to open up a new stage in this field. President Donald Trump issued executive orders in April and May mandating the reduction of domestic drug prices in the United States. Accompanying White House fact sheets refer to the high cost Americans pay for prescriptions, which is 2.78 times higher than the OECD average. Prescription costs are also 3.47 times higher than in Japan. Trump sees these high costs to consumers as a serious issue. In Japan, a national drug pricing system sets medication prices, enabling access to affordable treatments due to governmental oversight. In contrast, US pharmaceutical companies can set prices freely. This often results in higher charges than in other countries. Following his May 12 executive order, Trump stated that his orders would cut prices by 59% to as much as 90% to align with the levels of other countries. This could potentially result in significant revenue losses for the pharmaceutical industry. In the case of Japan, major pharmaceutical companies such as Takeda Pharmaceutical Company Limited and Astellas Pharma Inc earn over 30% of their revenue from the US. According to his comments, the President could impose additional tariffs on foreign-manufactured drugs if prices are not reduced. In the search for new drugs and treatments (Screenshot, ©FRONTEO Inc) One major reason for rising drug prices is the increasing cost of research and development. The average R&D spending by Japanese pharmaceutical companies rose from ¥30.2 billion JPY ($298.7 million USD) in 1993 to 163.3 billion ($1.13 billion) in 2019 — a 5.4-fold increase over 26 years. US companies saw an even sharper rise, from $841 million (¥121.1 billion) to $7.449 billion (¥1.0725 trillion). That marked an 8.8-fold increase. Moreover, investing in R&D doesn't guarantee success. The probability of developing a successful drug in Japan dropped from 1 in 13,000 two decades ago to 1 in 23,000 recently. Despite the increasing costs, results are scarce. Consequently, the R&D-to-revenue ratio rose from about 10% in 1993 to around 18% in 2019 in both countries. Introducing KIBIT. (Screenshot ©FRONTEO Inc) AI is being eyed as a solution to reduce R&D costs by dramatically cutting time and expenses. Drug development involves four stages: Basic research & target identification Compound optimization Preclinical trials and Clinical trials. Many AI vendors are involved in drug discovery. In particular, they focus on reducing costs in the third (preclinical) and fourth (clinical) stages. However, most companies have yet to tackle the critical first stage — target identification. Introducing KIBIT. (Screenshot, ©FRONTEO Inc) The first enterprise to address this initial stage is the Japanese company FRONTEO. Utilizing its proprietary natural language processing AI engine KIBIT, the company analyzes vast medical and pharmaceutical literature to generate innovative drug ideas that researchers may not have considered. Human thinking is inherently biased. The more experienced a researcher is, the more difficult it becomes to identify novel molecular targets. Stated another way, the bias of experience often blocks new ideas. KIBIT, however, is free from such biases. It identifies new molecular targets that might be effective against specific diseases. To do so, it analyzes vast amounts of academic literature. It can even derive specific hypotheses. Furthermore, KIBIT can identify and suggest highly disease-relevant target molecules that are not explicitly mentioned in the literature. This significantly enhances drug discovery potential. How KIBIT works. (Screenshot, ©FRONTEO Inc) Only a few countries have the capacity to develop new drugs. In 2024, among newly approved pharmaceuticals in Japan, the US, and Europe, the US led with 143 products. Japan followed with just 12, roughly equal to the United Kingdom's 10. According to the statistics "Nationalities of companies creating the top 100 drugs in the world by sales (2022),": United States – 52 United Kingdom – 10 Switzerland – 9 Germany – 8 Denmark – 8 Japan – 7 Most countries, other than the US, struggle to produce blockbuster drugs. In this context, hopes are high for FRONTEO's KIBIT. If it can consistently generate innovative new drugs efficiently, it may help deliver affordable medicines to those in need, without Mr Trump's intervention. FRONTEO's AI drug discovery service, utilizing KIBIT, is already being adopted by several major pharmaceutical companies. Those leveraging KIBIT to create new drugs could become game changers in the industry. This article is contributed by FRONTEO Inc, a supporting member of JAPAN Forward. (Read the report in Japanese.) Author: FRONTEO Inc. このページを 日本語 で読む


Global News
a day ago
- Global News
RFK Jr. removes all 17 members of U.S. vaccine advisory panel
U.S. Health Secretary Robert F. Kennedy Jr. on Monday removed every member of a scientific committee that advises the Centers for Disease Control and Prevention on how to use vaccines and pledged to replace them with his own picks. Major physicians and public health groups criticized the move to oust all 17 members of the Advisory Committee on Immunization Practices. Kennedy, who was one of the nation's leading anti-vaccine activists before becoming the nation's top health official, has not said who he would appoint to the panel, but said it would convene in just two weeks in Atlanta. Although it's typically not viewed as a partisan board, the Biden administration had installed the entire committee. 'Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028,' Kennedy wrote in a Wall Street Journal opinion piece. 'A clean sweep is needed to re-establish public confidence in vaccine science.' Story continues below advertisement Kennedy said the committee members had too many conflicts of interest. Committee members routinely disclose any possible conflicts at the start of public meetings. Dr. Georges Benjamin, executive director of the American Public Health Association, called Kennedy's mass ouster 'a coup.' 'It's not how democracies work. It's not good for the health of the nation,' Benjamin told The Associated Press. 0:37 RFK announces COVID vaccine removal from immunization schedule for pregnant women and children Benjamin said the move raises real concerns about whether future committee members will be viewed as impartial. He added that Kennedy is going against what he told lawmakers and the public, and the public health association plans to watch Kennedy 'like a hawk.' Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'He is breaking a promise,' Benjamin said. 'He said he wasn't going to do this.' Dr. Bruce A. Scott, president of the American Medical Association, called the committee a trusted source of science- and data-driven advice and said Kennedy's move, coupled with declining vaccination rates across the country, will help drive an increase in vaccine-preventable diseases. Story continues below advertisement 'Today's action to remove the 17 sitting members of ACIP undermines that trust and upends a transparent process that has saved countless lives,' Scott said in a statement. Republican Sen. Bill Cassidy of Louisiana, a doctor who had expressed reservations about Kennedy's nomination but voted to install him as the nation's health secretary nonetheless, said he had spoken with Kennedy moments after the announcement. 'Of course, now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion,' Cassidy said in a social media post. 'I've just spoken with Secretary Kennedy, and I'll continue to talk with him to ensure this is not the case.' 9:34 RFK Jr. and Elizabeth Warren get into heated debate over vaccine question at confirmation hearing The committee had been in a state of flux since Kennedy took over. Its first meeting this year had been delayed when the U.S. Department of Health and Human Services abruptly postponed its February meeting. Story continues below advertisement During Kennedy's confirmation, Cassidy had expressed concerns about preserving the committee, saying he had sought assurances that Kennedy would keep the panel's current vaccine recommendations. Kennedy did not stick to that. He recently took the unusual step of changing COVID-19 recommendations without first consulting the advisers. The webpage that featured the committee's members was deleted Monday evening, shortly after Kennedy's announcement.


Winnipeg Free Press
2 days ago
- Winnipeg Free Press
RFK Jr. ousts entire CDC vaccine advisory committee
WASHINGTON (AP) — Health Secretary Robert F. Kennedy Jr. on Monday removed every member of a scientific committee that advises the Centers for Disease Control and Prevention on how to use vaccines and pledged to replace them with his own picks. The 17-member Advisory Committee on Immunization Practices had been in a state of flux since Kennedy took over. Its first meeting this year had been delayed when the U.S. Department of Health and Human Services abruptly postponed its February meeting. Kennedy, who was one of the nation's leading anti-vaccine activists before becoming the nation's top health official, recently took the unusual step of changing COVID-19 recommendations without first consulting the panel. Kennedy, in a Wall Street Journal opinion piece, said the committee members had too many conflicts of interest. Committee members routinely disclose any possible conflicts at the start of public meetings. Wednesdays Columnist Jen Zoratti looks at what's next in arts, life and pop culture. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.